About
Chris Bostick focuses on healthcare investments at OCV Partners, working on technologies that apply interdisciplinary methods to precision medicine. Before joining OCV, he completed postdoctoral work at the Institute for Genomic Medicine at Columbia University, studying precision medicine approaches to genetic neurological disorders, and earlier researched drug metabolism, bioelectronics/biosensors, and nanotechnology during his PhD. He holds a B.S. in Biology with a business minor from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University.
Invests in
BiotechDigital HealthHealthtechMedical Devices
Experience
- OCVPartnercurrent2021 β present
- OCVVice President, Investments2019 β 2021Greater Los Angeles Area
- OCVSenior Associate, Investments2018 β 2019Greater Los Angeles Area
- Milken InstituteYoung Leaders Circle2024 β 2026
- Columbia University Medical CenterPostdoctoral Fellow2016 β 2018Greater New York City Area
- West Virginia UniversityPh.D. Candidate, Pharmacological and Pharmaceutical Sciences2010 β 2015Greater Pittsburgh Area
- Weizmann Institute of ScienceVisiting Scholar2015RehΜ±ovot, Central, Israel
- Wegman's PharmacyCertified Pharmacy Technician2009 β 2010
Education
- West Virginia UniversityDoctor of Philosophy (Ph.D.), Pharmacological and Pharmaceutical Sciences2010 β 2015
- Cornell UniversityBachelor of Science (B.S.), Biological Sciences2005 β 2009
Skills & more
+12 more
E-beam EvaporationDynamic Light ScatteringLC-MSUV-Vis SpectorscopyAutodockSputter DepositionProtein ImmobilizationCell CultureHigh-Performance Liquid Chromatography (HPLC)PharmaceuticsData AnalysisDrug DeliveryFrom Chris's professional profile.
Same school
Also attended West Virginia University15
+ 9 more
Also attended Cornell University509
+ 503 more
Shared employers
Also worked at OCV6
Also worked at Milken Institute51
+ 45 more
Also worked at Columbia University Medical Center18
+ 12 more
Also worked at West Virginia University1
Deals Β· 2
Rad AILed round
via OCV Partners
TORL BioTherapeuticsLed round
via OCV Partners
Attribution from SEC filings, press coverage, and firm rosters.


























.png)



